Skip to main content
Home

Dedicated to discovery

  • Company
    • About us
    • Careers
    • Events
  • Support
    • Laboratory Planning
  • Contact
  • EN
  • DE
  • ES
  • FR
  • IT
  • PT
Home
  • Products
    • PURELAB®
      • PURELAB® Dispenser
      • PURELAB® Flex
      • PURELAB® Quest
      • PURELAB® Pharma Compliance
      • PURELAB® Chorus 1 Complete
      • PURELAB® Chorus 1
      • PURELAB® Chorus 2
      • PURELAB® Chorus 3
      • Purelab Chorus 2+ (RO/DI/UV) / (RO/EDI/UV)
    • CENTRA®
      • CENTRA® R60/120
      • CENTRA® R200
      • CENTRA® RDS
    • MEDICA®
      • MEDICA® 150
      • MEDICA® 7/15
      • MEDICA® BIOX 2024
      • MEDICA® Pro-R & Pro-RE
      • MEDICA® R200
      • MEDICA® EDI 15/30
      • MEDICA® Pro-LPS
      • MEDICA® Pro EDI 60/120
      • MEDICA® BIOX
      • Hubgrade
    • BIOPURE®
      • BIOPURE® 300/600
    • PURENERGY 30
    • ELGA Full Product Range
  • Applications
    • Atomic Absorption Spectroscopy
    • Cell and Tissue Culture
    • Clinical Biochemistry
    • Electrochemistry
    • Gas Chromatography
    • General lab water requirement
    • High Performance Liquid Chromatography (HPLC)
    • Immunochemistry
    • Liquid Chromatography
      • High Performance Liquid Chromatography
    • Mass Spectrometry
    • Microbiology
    • Molecular Biology
    • Spectrophotometry
  • Technologies
    • Activated Carbon
    • Electrodeionization (EDI)
    • Filtration
    • Ion Exchange
    • PureSure
    • Reverse Osmosis
    • Ultraviolet
  • Impurities In Water
    • Dissolved Gases
    • Inorganic Compounds
    • Microorganisms & Bacteria
    • Organic Compounds
    • Particulates
  • Knowledge
    • BROSCHÜREN
    • Blog
    • Case Studies
    • Ultrapure water
    • Guides and White Papers
  • Where to buy
  • Contact us
Home
  • Contact us
  • Products
    • PURELAB®
      • PURELAB® Dispenser
      • PURELAB® Flex
      • PURELAB® Quest
      • PURELAB® Pharma Compliance
      • PURELAB® Chorus 1 Complete
      • PURELAB® Chorus 1
      • PURELAB® Chorus 2
      • PURELAB® Chorus 3
      • Purelab Chorus 2+ (RO/DI/UV) / (RO/EDI/UV)
    • CENTRA®
      • CENTRA® R60/120
      • CENTRA® R200
      • CENTRA® RDS
    • MEDICA®
      • MEDICA® 150
      • MEDICA® 7/15
      • MEDICA® BIOX 2024
      • MEDICA® Pro-R & Pro-RE
      • MEDICA® R200
      • MEDICA® EDI 15/30
      • MEDICA® Pro-LPS
      • MEDICA® Pro EDI 60/120
      • MEDICA® BIOX
      • Hubgrade
    • BIOPURE®
      • BIOPURE® 300/600
    • PURENERGY 30
    • ELGA Full Product Range
  • Applications
    • Atomic Absorption Spectroscopy
    • Cell and Tissue Culture
    • Clinical Biochemistry
    • Electrochemistry
    • Gas Chromatography
    • General lab water requirement
    • High Performance Liquid Chromatography (HPLC)
    • Immunochemistry
    • Liquid Chromatography
      • High Performance Liquid Chromatography
    • Mass Spectrometry
    • Microbiology
    • Molecular Biology
    • Spectrophotometry
  • Technologies
    • Activated Carbon
    • Electrodeionization (EDI)
    • Filtration
    • Ion Exchange
    • PureSure
    • Reverse Osmosis
    • Ultraviolet
  • Impurities In Water
    • Dissolved Gases
    • Inorganic Compounds
    • Microorganisms & Bacteria
    • Organic Compounds
    • Particulates
  • Knowledge
    • BROSCHÜREN
    • Blog
    • Case Studies
    • Ultrapure water
    • Guides and White Papers
  • Where to buy
  • Contact us
  • Company
    • About us
    • Careers
    • Events
  • Support
    • Laboratory Planning
  • Contact
  • EN
  • DE
  • ES
  • FR
  • IT
  • PT
  • Privacy policy
  • Terms & Conditions
  • Global Legal Compliance
  • Patents
  • Trademarks
  • Impressum
  • Understanding the Roles of Traditional Chinese Medicines in Fighting Heart Disease

Understanding the Roles of Traditional Chinese Medicines in Fighting Heart Disease

8 Jun 2020
- by Dr Paul Whitehead

Ancient Chinese medical books in the Qing Dynasty, the Chinese herbal medicine on the table

Traditional Chinese medicines have been used for centuries with success in tackling many conditions.

However, often, the detailed mechanisms of their effectiveness have not been fully understood and investigations continue. Work has been reported in two very recent papers by Yi Wang and co-workers examining different aspects of heart disease; they have investigated both the effects of various intermediaries and their links to traditional Chinese medicines. 

Heart attacks are clearly a major cause of premature death globally. Early reperfusion of the ischemic region of the heart (MI/R) is a key stage in restoring cardiac function but damage during this process is a major source of problems (1). Although the molecular mechanisms of MI/R injury are not fully understood, recent studies (2) indicated that microRNAs are key molecular players in the processes involved. MicroRNAs are small non-coding RNA molecules (containing about 22 nucleotides) that function in RNA silencing and post-transcriptional regulation of gene expression. Working with rats, Yi Wang and Xiaoping Zhao in Hangzhou have identified a critical role for microRNA miR-30c-5p during MI/R injury (3). It was found to inhibit oxidative stress-induced heart-muscle cell injury and regulate p53 expression.  MiR-30c-5p has been identified as a potential target for regulating cell damage during MI/R injury, as illustrated in the figure.

MI/R injury


Wang and Zhao have also analysed the components of panax notoginseng saponins (PNS), a traditional Chinese medicine with known benefits in the treatment of human MI/R injury. Only ginsenoside Re was found to increase cell viability. The effectiveness of PNS during MI/R injury can be accounted for by the results showing that PNS and ginsenoside Re significantly increased the levels of miR-30c-5p in MI/R injury cells and reduced the expression of p53 protein. Inhibition of miR-30c-5p blocked the protection offered by PNS.

In a second paper (4) Yi Wang examined the mechanisms behind the use of Tongmaiyangxin (TMYX) pills in treating cardiac hypertrophy, a thickening of heart muscle closely linked with heart remodelling. It is often associated with significantly increased risks of heart failure and malignant irregularities in heart beat. TMYX consists of 11 herbs and has been found to have a number of beneficial effects in various aspects of heart disease (5). Wang examined specifically its effect on cardiac hypertrophy.

TMYX was found to inhibit the development of cardiac hypertrophy and heart failure as well as increasing the expression of the anti-hypertrophic protein Sirt3. Sirt3 has been found to be a key regulator of cardiac hypertrophy (6). The team used high-content screening – a technique based on automated microscopy to measure various biomarkers in a single cell – to test the compounds separated from TMYX. Licoisoflavone A, licoricone, licorisoflavan A and emodin showed anti-hypertrophy effects. Of these, licoisoflavone A was shown to provide increased expression of Sirt3 and, hence, a therapeutic effect on cardiac hypertrophy.

Purified water produced by an ELGA PURELAB flex system was used throughout these research studies. High purity water (such as ultrapure water) is essential to ensure the viability of the experimentation. Very low contamination from bacteria and biologically active species is particularly critical.

References:

  1. D.M.Yellom, D.J.Hausenloy, Myocardial reperfusion injury, N. Engl. J. Med. 357 (2007) 1121-35
  2. Z. Chen, Y. Qi, C. Gao, Cardiac myocyte protective effect of microRNA-22 during ischemia and reperfusion through disrupting the caveolin-3/eNOS signalling, Int. J. Clin. Exp. Pathol. 8 (2015) 4614-26.
  3. L. Wang, X. Chen, Y. Wang, L. Zhao, X. Zhao and Yi. Wang, MiR-30c-5p mediates the effects of panax notoginseng saponins in myocardial ischemia reperfusion injury by inhibiting oxidative stree-induced cell damage, Biomed. & Pharmacotherapy, 125 (2020) 109963.
  4. R. Guo, N. Liu, H. Liu, J. Zhang, H. Zhang, Y. Wang, M. Baruscotti, L. Zhao and Yi Wang, High content screening identifies licoisoflavone A as a bioactive compound of Tongmaiyangxin pills to restrain cardiomyocyte hypertrophy via activating Sirt3, Phytomedicine 68 (2020) 153171
  5. L. Ke, L. Sun, K.J. Gao, Tongmaiyangxin pill for treatment of ventricular premature in coronary heart disease with deficiency syndrome of both qi and yin: a multi-center clinical trial, Chin. J. Integr. Med. Cardio. Cerebrovasc. Dis. 8 (4) (2010) 401.
  6. N.R. Sundaresan, G. Madhu, S.B. Rajamohan, I. Ayman and M.P. Gupta, Sirt3 blocks the cardiac hypertrophic response by augmenting Fox03a-dependent antioxidant defense mechanisms in mice, J. Clin. Invest. 119 (9) (2009) 2758-71.
     
  • Sales Enquiry
  • Get a Quote
  • Technical Support
  • Find an Approved Partner

Sales Enquiry

At ELGA LabWater, we have exciting offers and news about our products and services that we hope you’d like to hear about. We will use your information to predict what you might be interested in. We will treat your data with respect and you can find the details in our Privacy Policy.

ELGA LabWater works with a network of Approved Partners. In order to answer your questions or enquiries, we may pass your contact details to an Approved Partner, who may contact you directly. 

I'd like to receive updates from ELGA LabWater & ELGA Approved Partners based on my details.

Get a Quote

At ELGA LabWater, we have exciting offers and news about our products and services that we hope you’d like to hear about. We will use your information to predict what you might be interested in. We will treat your data with respect and you can find the details in our Privacy Policy.

ELGA LabWater works with a network of Approved Partners. In order to answer your questions or enquiries, we may pass your contact details to an Approved Partner, who may contact you directly. 

I'd like to receive updates from ELGA LabWater & ELGA Approved Partners based on my details.

Technical Support

At ELGA LabWater, we have exciting offers and news about our products and services that we hope you’d like to hear about. We will use your information to predict what you might be interested in. We will treat your data with respect and you can find the details in our Privacy Policy.

ELGA LabWater works with a network of Approved Partners. In order to answer your questions or enquiries, we may pass your contact details to an Approved Partner, who may contact you directly. 

Call us

Can't find what you are looking for?

Support Number
+44 (0)20 3567 7300
United Kingdom Sales
+44 (0)1628 879 704
United States of America Sales
+1 877-315-3542
France Sales
+33 1 40 83 65 00
China Sales
+86 400-616-8882

 

ELGA LabWater US Headquarters

ELGA LabWater North America
5 Earl Ct Suite 100
Woodridge, IL 60517
USA

Tel: 630-343-5251

Case Studies

  • Abbott Diagnostics
  • DASA Medical Diagnostics
  • NeoDIN Medical Institute
  • North Staffordshire NHS Trust
  • Olsberg Vocational College

Resources

  • Learn About Ultrapure Water
  • Guides and White Papers
  • Purification Technologies
  • Applications
  • Impurities In Water
  • Latest Blog
  • Water Purity - Different Types of Pure Water
  • What is Clinical Laboratory Reagent Water (CLSI)?
  • What is Total Organic Carbon (TOC)?

© VWS (UK) Ltd. trading as ELGA LabWater. 2025 - All rights reserved.
ELGA is the global laboratory water brand name of Veolia.

  • Privacy policy
  • Terms & Conditions
  • Global Legal Compliance
  • Patents
  • Trademarks
  • Impressum
  • Language
    • Deutsch
    • English
    • Español
    • Français
    • Italiano
    • Português
    • 日本語
    • 中文
  • Other Veolia Sites
    • Veolia
    • Veolia Foundation
    • Veolia Water Technologies
Elga Veolia
TOP

© 2017 ELGA Veolia